Filing Flows › Vistagen Therapeutics (VTGN) › Q3 FY25
Vistagen Therapeutics (VTGN) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Feb 13, 2025
Vistagen Therapeutics (VTGN) reported revenue of $234K for the third quarter fiscal 2025 (Q3 FY25), -43% from a year earlier and +28% from the quarter before.
Vistagen Therapeutics, Q3 FY25: revenue $234K (-43% year over year), net loss $14.1M, operating cash flow −$10.3M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $234K | +28% | -43% |
| Operating profit | −$15.1M | — | — |
| Net earnings | −$14.1M | — | — |
| Operating cash flow | −$10.3M | — | — |
What changed
Revenue was $234K in Q3 FY25, down 43% year over year and up 28% from the previous quarter.
Operating costs exceeded revenue by $15.1M, an operating margin of -6461.5%. Total costs grew 85% against a revenue fall of 43%. The fastest-growing cost line was Research & development (+149%). The quarter ended with a net loss of $14.1M, wider than the previous quarter's $13.0M loss.
Operating cash flow was −$10.3M. Non-cash charges added back $39K of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items added $2.7M.
Questions
What was Vistagen Therapeutics' revenue in the third quarter fiscal 2025?
Vistagen Therapeutics (VTGN) reported revenue of $234K for the third quarter fiscal 2025 (Q3 FY25), -43% from a year earlier and +28% from the quarter before.